These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35257971)

  • 21. Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019.
    Adámková V; Mareković I; Szabó J; Pojnar L; Billová S; Horvat Herceg S; Kuraieva A; Możejko-Pastewka B
    Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):989-996. PubMed ID: 35596097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing
    Palombo M; Secci B; Bovo F; Gatti M; Ambretti S; Gaibani P
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study.
    La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F
    J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
    Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
    Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
    Sun S; Chen K; Kong X; Tian W; Niu S
    Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
    Sader HS; Carvalhaes CG; Huband MD; Mendes RE; Castanheira M
    Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):453-459. PubMed ID: 36810724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019.
    Jean SS; Lee YL; Hsu CW; Hsueh PR
    Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.
    Ito CAS; Bail L; Arend LNVS; Silva KO; Michelotto SS; Nogueira KDS; Tuon FF
    J Clin Microbiol; 2021 Nov; 59(12):e0153621. PubMed ID: 34586889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
    Carvalho TN; Kobs VC; Hille D; Deglmann RC; Melo LH; França PHC
    Rev Soc Bras Med Trop; 2023; 56():. PubMed ID: 36700602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
    Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
    Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
    Rossolini GM; Arhin FF; Kantecki M
    J Glob Antimicrob Resist; 2024 Mar; 36():123-131. PubMed ID: 38154750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.
    Emilie CM; Alice CM; Marine G; Farfour E; Pourbaix A; Dortet L; Lucie L; Marc V
    Eur J Clin Microbiol Infect Dis; 2024 Apr; 43(4):777-784. PubMed ID: 38277033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
    Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
    Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
    Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
    Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
    Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
    Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
    Xiong L; Wang X; Wang Y; Yu W; Zhou Y; Chi X; Xiao T; Xiao Y
    WIREs Mech Dis; 2022 Nov; 14(6):e1571. PubMed ID: 35891616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.